MedPath

Evaluation and Compararison of diagnostic and prognostic accuracy of different biomarkers like Procalcitonin, CD64, Group II phospholipase A 2 and Human neutrophil lipocalin for adult sepsis and septic shock in sick patients admitted in Emergency Department.

Phase 4
Not yet recruiting
Conditions
Medical and Surgical,
Registration Number
CTRI/2025/06/088741
Lead Sponsor
Sanjay Gandhi Post Graduate Institute
Brief Summary

**Project summary-**

Thoughit’s well known that timely identification of septic shock is decisive toimprove any septic patient’s mortality, no biomarker is still existing todetect it in the initiation. Procalcitonin, CD64,Group II phospholipaseA 2, and Human neutrophil lipocalin are the promising one among 260 tested biomarkers.In our study, we want to compare the diagnostic accuracy of these biomarkers inseptic shock patients in our emergency department. Additionally, prognosticguidance if any will be seen.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
118
Inclusion Criteria
  • 1 Age more than 18 years 2.
  • sepsis according to sepsis 3 criteria.
  • 3, emergency department.
Exclusion Criteria
  • Not giving consent for test.
  • Patients with immune-related diseases- can influence biomarker level.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The diagnostic accuracy of CD64, PLA 2GIIA, HML and Procalcitonin in sepsis and septic shock patients in emergency department.1 year
Secondary Outcome Measures
NameTimeMethod
any correlation between mortality with admission biomarker levels & admission SOFA score.1 year

Trial Locations

Locations (1)

Department of Emergency Medicine

🇮🇳

Lucknow, UTTAR PRADESH, India

Department of Emergency Medicine
🇮🇳Lucknow, UTTAR PRADESH, India
Tanmoy Ghatak
Principal investigator
09455037848
tanmoyghatak@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.